Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SRILATA GUNDALA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1467646141
CMS profile
67012
Location
HINSDALE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,898.91

105 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,293.07 99
Long term medical supply or device loan $398.80 4
Education $207.04 2

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SRILATA GUNDALA

NPI 1467646141 · CMS profile ID 67012

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

HINSDALE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1467646141?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SRILATA GUNDALA, NPI 1467646141, CMS profile ID 67012. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1467646141?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SRILATA GUNDALA, NPI 1467646141, CMS profile ID 67012. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1467646141?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SRILATA GUNDALA, NPI 1467646141, CMS profile ID 67012, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1467646141?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

105 matching records · $2,898.91 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 105 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 105.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $20.9907/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141610443 CMS
Janssen Biotech, Inc. $27.3607/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078590917 CMS
AstraZeneca Pharmaceuticals LP $99.9907/08/2024 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1155841520 CMS
AstraZeneca Pharmaceuticals LP $2.4306/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105284017 CMS
AstraZeneca Pharmaceuticals LP $17.2606/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105887041 CMS
Janssen Biotech, Inc. $24.2806/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078590538 CMS
Gilead Sciences, Inc. $22.3906/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133800568 CMS
ABBVIE INC. $26.8706/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103850826 CMS
Alexion Pharmaceuticals, Inc. $16.9906/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1094037405 CMS
PFIZER INC. $26.8506/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131703466 CMS
Novartis Pharmaceuticals Corporation $21.9106/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086850029 CMS
PFIZER INC. $18.0406/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131349641 CMS
Regeneron Healthcare Solutions, Inc. $17.0506/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114061603 CMS
AstraZeneca Pharmaceuticals LP $23.8305/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104650837 CMS
Takeda Pharmaceuticals U.S.A., Inc. $26.3005/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144958396 CMS
Novartis Pharmaceuticals Corporation $25.9905/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086850031 CMS
Celgene Corporation $16.6105/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101154906 CMS
JAZZ PHARMACEUTICALS INC. $29.6705/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150216578 CMS
Mirati Therapeutics, Inc. $17.4405/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117171838 CMS
AstraZeneca Pharmaceuticals LP $18.6905/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105454427 CMS
Novartis Pharmaceuticals Corporation $11.7205/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086850027 CMS
AstraZeneca Pharmaceuticals LP $32.3304/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104442993 CMS
Tempus AI, Inc $9.2704/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150165710 CMS
Lilly USA, LLC $10.4004/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135414517 CMS
Janssen Biotech, Inc. $27.2504/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078590498 CMS
ABBVIE INC. $24.8904/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103850824 CMS
Amneal Pharmaceuticals LLC $27.2704/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139187788 CMS
GENZYME CORPORATION $28.4504/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139955953 CMS
Genentech USA, Inc. $31.8304/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133114853 CMS
Lilly USA, LLC $107.0504/05/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135429001 CMS
Lilly USA, LLC $20.2404/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135349491 CMS
Pharmacosmos Therapeutics Inc. $25.7203/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154822169 CMS
Bayer Healthcare Pharmaceuticals Inc. $16.4703/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086152357 CMS
PFIZER INC. $13.5903/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131302599 CMS
PFIZER INC. $26.2903/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131295391 CMS
PFIZER INC. $17.1003/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131288367 CMS
Alexion Pharmaceuticals, Inc. $24.5403/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093926504 CMS
Janssen Biotech, Inc. $19.8403/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078590738 CMS
ABBVIE INC. $26.8703/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103850822 CMS
Lilly USA, LLC $15.5503/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135414519 CMS
Novartis Pharmaceuticals Corporation $17.0803/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086850025 CMS
Janssen Biotech, Inc. $22.8302/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078590505 CMS
Regeneron Healthcare Solutions, Inc. $15.8902/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114061601 CMS
Mirati Therapeutics, Inc. $13.5302/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117171835 CMS
Astellas Pharma US Inc $27.4602/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139311598 CMS
Tempus AI, Inc $65.6802/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150165708 CMS
Tempus AI, Inc $6.0402/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150165706 CMS
Janssen Biotech, Inc. $29.1601/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078590796 CMS
Lilly USA, LLC $15.8901/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135398259 CMS
Novartis Pharmaceuticals Corporation $9.0701/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086850023 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $522.13 29
PY2020 $271.29 14
PY2021 $642.57 25
PY2022 $912.26 44
PY2023 $1,983.95 71
PY2024 $2,898.91 105
PY2025 $3,630.79 118

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,158,956.38 214
PY2024 Principal investigator $1,000,365.79 67
PY2023 Principal investigator $106,650.71 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

214 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Aadi Bioscience, Inc. $64,929.53 12/31/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/?TSC2 Genes (PRECISION 1) No dispute reported 06/30/2026 1255063022
Principal investigator 1 PFIZER INC. $35,750.00 12/31/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services PLLC
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228804925
Principal investigator 1 BeOne Medicines Ltd. $11,148.00 12/19/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services
A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma No dispute reported 06/30/2026 1190330707
Principal investigator 1 Janssen Research & Development, LLC $700.00 12/19/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES PL
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175414359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 12/19/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184279122
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,000.00 12/19/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184279124
Principal investigator 1 PFIZER INC. $35,750.00 12/18/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services PLLC
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228804919
Principal investigator 1 PFIZER INC. $19,908.70 12/17/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228714333
Principal investigator 1 PFIZER INC. $356.50 12/17/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228714337
Principal investigator 1 PFIZER INC. $23,590.88 12/17/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228714411
Principal investigator 1 PFIZER INC. $461.25 12/17/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228714447
Principal investigator 1 PFIZER INC. $2,987.04 12/17/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228714451
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,000.00 12/17/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVIC
Fruquintinib No dispute reported 06/30/2026 1223289876
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 12/17/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVIC
Fruquintinib No dispute reported 06/30/2026 1223289878
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $110.81 12/11/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184274667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $641.56 12/11/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184274669
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $183.68 12/11/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184274671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $161.00 12/11/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184274673
Principal investigator 1 AstraZeneca Pharmaceuticals LP $47,950.00 12/10/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic NSCLC With High PD-L1 Expression and Without Actionable Genomic Alterations (TROPION-Lung10) No dispute reported 06/30/2026 1185539509
Principal investigator 1 AstraZeneca Pharmaceuticals LP $37,929.40 12/05/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES
A Phase III Randomized Double blind Multicenter Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum based Chemotherapy for the First line Treatment of Patients with Metastatic Non squamous Non small Cell Lung Cancer Whose Tumors Express PDL1 ARTEMIDE Lung03 No dispute reported 06/30/2026 1185539515
Principal investigator 1 ABBVIE INC. $1,015.20 12/04/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202527938
Principal investigator 1 ABBVIE INC. $100.00 12/04/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202527940
Principal investigator 1 PFIZER INC. $57,300.60 12/04/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228714042
Principal investigator 1 PFIZER INC. $7.50 12/04/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228714413
Principal investigator 1 PFIZER INC. $12,247.56 12/04/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228714523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,940.28 12/04/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184269289
Principal investigator 1 ABBVIE INC. $1,270.98 12/03/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (AndroMETa-CRC) No dispute reported 06/30/2026 1202526396
Principal investigator 1 AstraZeneca Pharmaceuticals LP $42,207.20 12/03/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES
a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer No dispute reported 06/30/2026 1185539505
Principal investigator 1 PFIZER INC. $208.00 12/02/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228714040
Principal investigator 1 PFIZER INC. $82.08 12/02/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228714335
Principal investigator 1 PFIZER INC. $19,628.80 12/02/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228714449
Principal investigator 1 PFIZER INC. $768.00 12/02/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228714521
Principal investigator 1 ABBVIE INC. $8,998.98 11/26/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (AndroMETa-CRC) No dispute reported 06/30/2026 1202525520
Principal investigator 1 ABBVIE INC. $2,431.56 11/26/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (AndroMETa-CRC) No dispute reported 06/30/2026 1202525522
Principal investigator 1 PFIZER INC. $10,965.52 11/26/2025 Non-covered Recipient Entity
HOPE AND HEALING CLINICAL RESEARCH
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228807072
Principal investigator 1 PFIZER INC. $425.00 11/26/2025 Non-covered Recipient Entity
HOPE AND HEALING CLINICAL RESEARCH
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228807077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $650.00 11/25/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184264537
Principal investigator 1 Daiichi Sankyo Inc. $4,500.00 11/24/2025 Non-covered Recipient Entity
Hope And Healing Cancer Services Hinsdale Office
DS8201-793 No dispute reported 06/30/2026 1225317489
Principal investigator 1 Daiichi Sankyo Inc. $4,806.00 11/24/2025 Non-covered Recipient Entity
Hope And Healing Cancer Services Hinsdale Office
DS8201-793 No dispute reported 06/30/2026 1225317491
Principal investigator 1 Daiichi Sankyo Inc. $2,000.00 11/24/2025 Non-covered Recipient Entity
Hope And Healing Cancer Services Hinsdale Office
DS8201-793 No dispute reported 06/30/2026 1225317493
Principal investigator 1 Daiichi Sankyo Inc. $1,500.00 11/24/2025 Non-covered Recipient Entity
Hope And Healing Cancer Services Hinsdale Office
DS8201-793 No dispute reported 06/30/2026 1225317495
Principal investigator 1 Daiichi Sankyo Inc. $1,000.00 11/24/2025 Non-covered Recipient Entity
Hope And Healing Cancer Services Hinsdale Office
DS8201-793 No dispute reported 06/30/2026 1225317497
Principal investigator 1 Daiichi Sankyo Inc. $2,800.00 11/24/2025 Non-covered Recipient Entity
Hope And Healing Cancer Services Hinsdale Office
DS8201-793 No dispute reported 06/30/2026 1225317499
Principal investigator 1 Daiichi Sankyo Inc. $2,000.00 11/24/2025 Non-covered Recipient Entity
Hope And Healing Cancer Services Hinsdale Office
DS8201-793 No dispute reported 06/30/2026 1225317501
Principal investigator 1 Daiichi Sankyo Inc. $24,000.00 11/24/2025 Non-covered Recipient Entity
Hope And Healing Cancer Services Hinsdale Office
DS8201-793 No dispute reported 06/30/2026 1225317503
Principal investigator 1 Genmab U.S., Inc. $2,200.00 11/24/2025 Non-covered Recipient Entity
HOPE & HEALING CANCER SERVICES
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235930681
Principal investigator 1 ABBVIE INC. $45.00 11/20/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202524852
Principal investigator 1 Genmab U.S., Inc. $550.00 11/20/2025 Non-covered Recipient Entity
HOPE & HEALING CANCER SERVICES
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235930685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $161.00 11/20/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184263727
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $560.14 11/20/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184263729
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.82 11/20/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184263731
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $360.18 11/20/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184263733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $477.48 11/20/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184263735
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 11/14/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES PL
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175414396
Principal investigator 1 ABBVIE INC. $100.00 11/13/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202524157
Principal investigator 1 BeOne Medicines Ltd. $11,148.00 11/12/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services
A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma No dispute reported 06/30/2026 1190342838
Principal investigator 1 PFIZER INC. $5,500.00 11/07/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services PLLC
A PHASE 2B3 RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGROMAB PF06946860 COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRSTLINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA No dispute reported 06/30/2026 1228818092
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,750.53 11/07/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184259085
Principal investigator 1 ABBVIE INC. $7,000.00 11/06/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202523361
Principal investigator 1 ABBVIE INC. $7,000.00 11/06/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202523363
Principal investigator 1 ABBVIE INC. $5,364.90 11/05/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202522111
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,117.20 11/05/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVIC
Fruquintinib No dispute reported 06/30/2026 1223288055
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,466.80 11/05/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVIC
Fruquintinib No dispute reported 06/30/2026 1223288083
Principal investigator 1 ABBVIE INC. $28.00 10/30/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202519769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $333.96 10/29/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184253720
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,079.66 10/29/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184253722
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 10/29/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184253724
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.82 10/29/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184253726
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $104.00 10/29/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184253728
Principal investigator 1 Novartis Pharmaceuticals Corporation $587,650.48 10/28/2025 Non-covered Recipient Entity
HOPE AND HEALING CARE
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) No dispute reported 06/30/2026 1190309836
Principal investigator 1 Janssen Research & Development, LLC $1,511.00 10/24/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES PL
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175414329
Principal investigator 1 Janssen Research & Development, LLC $4,195.00 10/24/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES PL
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175414353
Principal investigator 1 ABBVIE INC. $80.00 10/23/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202518323
Principal investigator 1 ABBVIE INC. $200.00 10/23/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202518339
Principal investigator 1 ABBVIE INC. $50.00 10/21/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202517609
Principal investigator 1 AstraZeneca Pharmaceuticals LP $37,929.40 10/17/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES
Artemide Lung02 a phase III global study of rilvegostomig or pembrolizumab for patients with metastatic squamous non small cell lung cancer No dispute reported 06/30/2026 1185539503
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,914.80 10/16/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184250721
Principal investigator 1 BeOne Medicines USA, Inc. $26,600.00 10/14/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services
A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma No dispute reported 06/30/2026 1190329709
Principal investigator 1 Daiichi Sankyo Inc. $370.00 10/14/2025 Non-covered Recipient Entity
Hope And Healing Cancer Services Hinsdale Office
DS8201-793 No dispute reported 06/30/2026 1225317485
Principal investigator 1 Daiichi Sankyo Inc. $945.00 10/14/2025 Non-covered Recipient Entity
Hope And Healing Cancer Services Hinsdale Office
DS8201-793 No dispute reported 06/30/2026 1225317487
Principal investigator 1 Genmab U.S., Inc. $716.30 10/14/2025 Non-covered Recipient Entity
HOPE & HEALING CANCER SERVICES
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235930689
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 10/13/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES PL
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib No dispute reported 06/30/2026 1175414372
Principal investigator 1 ABBVIE INC. $13,146.30 10/09/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202515297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,940.28 10/09/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184248988
Principal investigator 1 Genentech, Inc. $37,000.00 10/06/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services PLLC
A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON−SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1211613223
Principal investigator 1 Janssen Research & Development, LLC $1,520.00 10/06/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES PL
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175414429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.82 10/03/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184244715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $208.00 10/03/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184244717
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $311.19 10/03/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184244719
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.00 10/03/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184244721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31,166.08 10/03/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184244723
Principal investigator 1 PFIZER INC. $1,128.60 09/30/2025 Non-covered Recipient Entity
Hope and Healing CancerService
A PHASE 2B3 RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGROMAB PF06946860 COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRSTLINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA No dispute reported 06/30/2026 1228812176
Principal investigator 1 PFIZER INC. $25,250.00 09/27/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services PLLC
A PHASE 2B3 RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGROMAB PF06946860 COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRSTLINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA No dispute reported 06/30/2026 1228836103
Principal investigator 1 ABBVIE INC. $100.00 09/25/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202512408
Principal investigator 1 ABBVIE INC. $5,240.70 09/23/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202511930
Principal investigator 1 ABBVIE INC. $2,200.00 09/18/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202511290
Principal investigator 1 ABBVIE INC. $13.55 09/18/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202511608
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,750.53 09/12/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184236606
Principal investigator 1 ABBVIE INC. $143.09 09/11/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202510790
Principal investigator 1 ABBVIE INC. $10,167.50 09/11/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202510792
Principal investigator 1 ABBVIE INC. $137.50 09/11/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202510794
Principal investigator 1 BeOne Medicines Ltd. $11,148.00 09/05/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services
A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma No dispute reported 06/30/2026 1190342768
Principal investigator 1 BeOne Medicines Ltd. $22,296.00 09/05/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services
A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma No dispute reported 06/30/2026 1190342773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,940.28 09/04/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184235225
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31,166.08 09/04/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184235227
Principal investigator 1 ABBVIE INC. $3,375.00 09/03/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202507185
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $70.00 08/27/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES
Fruquintinib No dispute reported 06/30/2026 1223284651
Principal investigator 1 ABBVIE INC. $8,673.75 08/26/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202505845
Principal investigator 1 PFIZER INC. $1,706.40 08/22/2025 Non-covered Recipient Entity
Hope and Healing CancerService
A PHASE 2B3 RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGROMAB PF06946860 COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRSTLINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA No dispute reported 06/30/2026 1228812170
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $81.42 08/21/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184229771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $645.15 08/21/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184229773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,498.82 08/14/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184228343
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31,166.08 08/14/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184228345
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,431.47 08/14/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184228347
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $650.00 08/13/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES
Fruquintinib No dispute reported 06/30/2026 1223284153
Principal investigator 1 ABBVIE INC. $550.00 08/07/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202503941
Principal investigator 1 Coherus Oncology, Inc. $3,700.00 08/04/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES
SRF114-101 No dispute reported 06/30/2026 1235252420
Principal investigator 1 Janssen Research & Development, LLC $1,720.00 08/04/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES LL C
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175414404
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,084.80 08/01/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES
Fruquintinib No dispute reported 06/30/2026 1223283563
Principal investigator 1 PFIZER INC. $6,750.00 07/31/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services PLLC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228843490
Principal investigator 1 ABBVIE INC. $2,200.00 07/29/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202500302
Principal investigator 1 Janssen Research & Development, LLC $700.00 07/25/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES LL C
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175414315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.82 07/22/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184217819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $335.84 07/22/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184217821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/22/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184217823
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 07/21/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES LL C
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan No dispute reported 06/30/2026 1175414416
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $93,498.24 07/17/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184217138
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $83.49 07/17/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184217140
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $715.53 07/17/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184217142
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $139.66 07/17/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184217144
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $560.14 07/17/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184217146
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,000.00 07/17/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184217148
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,750.53 07/17/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184217150
Principal investigator 1 PFIZER INC. $24,500.00 07/16/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services PLLC
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228843555
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,645.90 07/11/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES
Fruquintinib No dispute reported 06/30/2026 1223282548
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $70.00 07/11/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES
Fruquintinib No dispute reported 06/30/2026 1223282594
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,448.24 07/04/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184212901
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,466.56 07/04/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184212903
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.00 07/04/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184212907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $208.00 07/04/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184212909
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $70.00 07/02/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES
Fruquintinib No dispute reported 06/30/2026 1223282178
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,940.28 06/19/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184209239
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $110.81 06/19/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184209241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $241.50 06/19/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184209243
Principal investigator 1 Janssen Research & Development, LLC $641.00 06/16/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES LL C
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175414340
Principal investigator 1 Janssen Research & Development, LLC $173.00 06/16/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES LL C
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175414424
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $650.00 06/04/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184204045
Principal investigator 1 ABBVIE INC. $22,390.00 06/03/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202489453
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,084.80 06/02/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICE
Fruquintinib No dispute reported 06/30/2026 1223280556
Principal investigator 1 ABBVIE INC. $4,000.00 05/29/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202487091
Principal investigator 1 Coherus Oncology, Inc. $24,250.00 05/28/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES
SRF114-101 No dispute reported 06/30/2026 1235252405
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $936.61 05/28/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184198893
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,608.56 05/28/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184198895
Principal investigator 1 ABBVIE INC. $1,437.75 05/22/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202485947
Principal investigator 1 ABBVIE INC. $1,437.75 05/22/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202485949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,750.53 05/22/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184197653
Principal investigator 1 ABBVIE INC. $225.45 05/15/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202485185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $322.00 05/15/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184194695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $558.90 05/15/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184194697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $629.97 05/15/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184194699
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,160.57 05/15/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184194701
Principal investigator 1 PFIZER INC. $7,600.00 05/14/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228854775
Principal investigator 1 PFIZER INC. $1,000.00 05/12/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRSTLINE TREATMENT IN PARTICIPANTS WITH PDL1 HIGH 50 OF TUMOR CELLS EXPRESSING PDL1 LOCALLY ADVANCED UNRESECTABLE OR METASTATIC NONSMALL CELL LUNG CANCER BE6A LUNG02 No dispute reported 06/30/2026 1228822688
Principal investigator 1 Genmab U.S., Inc. $2,200.00 05/08/2025 Non-covered Recipient Entity
HOPE & HEALING CANCER SERVICES
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235930673
Principal investigator 1 ABBVIE INC. $5,240.70 05/07/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202484039
Principal investigator 1 Janssen Research & Development, LLC $1,520.00 05/05/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES LL C
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175414384
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,617.90 05/01/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICE
Fruquintinib No dispute reported 06/30/2026 1223278804
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,667.11 04/23/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184189029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $673.99 04/23/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184189031
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,970.76 04/23/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184189033
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,764.88 04/23/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184189035
Principal investigator 1 Janssen Research & Development, LLC $4,195.00 04/22/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES LL C
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175414334
Principal investigator 1 PFIZER INC. $27,750.00 04/09/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRSTLINE TREATMENT IN PARTICIPANTS WITH PDL1 HIGH 50 OF TUMOR CELLS EXPRESSING PDL1 LOCALLY ADVANCED UNRESECTABLE OR METASTATIC NONSMALL CELL LUNG CANCER BE6A LUNG02 No dispute reported 06/30/2026 1228852040
Principal investigator 1 ABBVIE INC. $5,240.70 04/08/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202474858
Principal investigator 1 Janssen Research & Development, LLC $905.00 04/07/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES LL C
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175414389
Principal investigator 1 Janssen Research & Development, LLC $700.00 04/07/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES LL C
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175414410
Principal investigator 1 Janssen Research & Development, LLC $700.00 04/07/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES LL C
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175414435
Principal investigator 1 Genmab U.S., Inc. $350.00 04/04/2025 Non-covered Recipient Entity
HOPE & HEALING CANCER SERVICES
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235930677
Principal investigator 1 ABBVIE INC. $1,437.75 04/03/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202469394
Principal investigator 1 ABBVIE INC. $22,200.00 04/03/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (AndroMETa-CRC) No dispute reported 06/30/2026 1202469397
Principal investigator 1 ABBVIE INC. $4,313.25 03/27/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202466721
Principal investigator 1 ABBVIE INC. $4,000.00 03/27/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (AndroMETa-CRC) No dispute reported 06/30/2026 1202467004
Principal investigator 1 Genmab U.S., Inc. $550.00 03/27/2025 Non-covered Recipient Entity
HOPE & HEALING CANCER SERVICES
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235930665
Principal investigator 1 Amgen Inc. $8,500.00 03/25/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES LLC
Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-nave Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301) No dispute reported 06/30/2026 1246642345
Principal investigator 1 Aadi Bioscience, Inc. $10,475.67 03/18/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services LLC
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes No dispute reported 06/30/2026 1181947065
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,774.80 03/14/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES
Fruquintinib No dispute reported 06/30/2026 1223276751
Principal investigator 1 ABBVIE INC. $4,000.00 03/13/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
M24-108 - A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202463214
Principal investigator 1 Janssen Research & Development, LLC $4,195.00 03/13/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES LL C
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175414322
Principal investigator 1 Janssen Research & Development, LLC $1,361.00 03/13/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES LL C
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175414344
Principal investigator 1 Janssen Research & Development, LLC $3,777.00 03/10/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES LL C
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175414365
Principal investigator 1 Genmab U.S., Inc. $263.90 03/06/2025 Non-covered Recipient Entity
HOPE & HEALING CANCER SERVICES
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235930637
Principal investigator 1 Genmab U.S., Inc. $977.60 03/06/2025 Non-covered Recipient Entity
HOPE & HEALING CANCER SERVICES
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235930640
Principal investigator 1 Genmab U.S., Inc. $550.00 03/06/2025 Non-covered Recipient Entity
HOPE & HEALING CANCER SERVICES
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235930651
Principal investigator 1 ABBVIE INC. $15,466.25 03/05/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
M24-108 - A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202455875
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 03/05/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES
Fruquintinib No dispute reported 06/30/2026 1223276005
Principal investigator 1 Janssen Research & Development, LLC $412.00 03/03/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES LL C
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175414350
Principal investigator 1 ABBVIE INC. $4,000.00 02/27/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202454421
Principal investigator 1 Genmab U.S., Inc. $1,179.42 02/13/2025 Non-covered Recipient Entity
HOPE & HEALING CANCER SERVICES
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235930654
Principal investigator 1 Genmab U.S., Inc. $550.00 02/13/2025 Non-covered Recipient Entity
HOPE & HEALING CANCER SERVICES
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235930662
Principal investigator 1 Genmab U.S., Inc. $392.60 02/13/2025 Non-covered Recipient Entity
HOPE & HEALING CANCER SERVICES
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235930669
Principal investigator 1 Janssen Research & Development, LLC $293.00 02/13/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES LL C
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175414377
Principal investigator 1 AstraZeneca UK Limited $84,418.99 02/05/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES
CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 No dispute reported 06/30/2026 1185539513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,534.00 02/05/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184152482
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,250.00 02/05/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184152484
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,000.00 02/05/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICESLLC LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184152486
Principal investigator 1 ABBVIE INC. $21,700.00 01/27/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202441279
Principal investigator 1 ABBVIE INC. $21,700.00 01/27/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES L
M24-108 - A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202441283
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $19,700.00 01/24/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES
Fruquintinib No dispute reported 06/30/2026 1223274459
Principal investigator 1 Janssen Research & Development, LLC $7,870.00 01/23/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES LL C
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175414311
Principal investigator 1 Genmab U.S., Inc. $8,534.50 01/16/2025 Non-covered Recipient Entity
HOPE & HEALING CANCER SERVICES
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235930658
Principal investigator 1 Aadi Bioscience, Inc. $2,716.60 01/14/2025 Non-covered Recipient Entity
Hope and Healing Cancer Services LLC
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes No dispute reported 06/30/2026 1181947063
Principal investigator 1 Genmab U.S., Inc. $8,534.50 01/09/2025 Non-covered Recipient Entity
HOPE & HEALING CANCER SERVICES
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235930644
Principal investigator 1 Genmab U.S., Inc. $1,331.00 01/09/2025 Non-covered Recipient Entity
HOPE & HEALING CANCER SERVICES
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235930647
Principal investigator 1 AstraZeneca Pharmaceuticals LP $27,389.61 01/03/2025 Non-covered Recipient Entity
HOPE AND HEALING CANCER SERVICES
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) No dispute reported 06/30/2026 1185539507